Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR21--Neoadjuvant Opdivo + Chemotherapy Significantly Improves Pathologic Complete Response in Patients w/ Resectable NSCLC in Phase 3 CheckMate -816 Trial